@article{article, title  = {{Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial}},

 publisher = {{BMJ}},

 url = {{https://eprints.whiterose.ac.uk/id/eprint/209330 }},

 year = {{2024}},

 month = {{2}},

 author = {{Brittain G and Petrie J and Duffy KEM and Glover R and Hullock K and Papaioannou D and Roldan E and Beecher C and Bursnall M and Ciccarelli O and Coles AJ et al}},

 doi = {{10.1136/bmjopen-2023-083582}},

 volume = {{14}},

 journal = {{BMJ Open}},

 issue = {{2}},

 note = {{Accessed on 2024/12/22}}}